Synaptic Transmission and Dysregulation: The Case for SYCN as a Drug Target and Biomarker

Target Name: SYCN

NCBI ID: G342898

SYCN

Synaptic Transmission and Dysregulation: The Case for SYCN as a Drug Target and Biomarker

Abstract:

SYNCP, or insulin synthesis-associated protein 1, is a protein that plays a crucial role in synaptic transmission, which is a critical aspect of neuronal communication. The abnormal activation of SYCN has been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. This article aims to provide an overview of the current research on SYCN, its potential drug targets, and its role as a biomarker for these disorders.

Introduction:

SYNCP is a protein that is expressed in various tissues and cell types, including neurons, glial cells, and blood vessels. It is a key regulator of synaptic transmission, which is the process by which neurons communicate with each other. The abnormal activation of SYCN has been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

Diseases associated with SYCN dysfunction:

SYNCP dysfunction has been implicated in the development and progression of several neurological and psychiatric disorders. One of the most well-documented examples is Alzheimer's disease, which is a degenerative brain disorder that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques. Studies have shown that individuals with Alzheimer's disease have lower levels of SYCP compared to healthy individuals.

Another example is Parkinson's disease, which is a neurodegenerative disorder that is characterized by the loss of dopamine-producing neurons in the brain. Similarly, studies have found that SYNCP is expressed at lower levels in patients with Parkinson's disease.

SYNCP's role in schizophrenia:

SYNCP has also been implicated in the development and maintenance of schizophrenia. Studies have shown that individuals with schizophrenia have lower levels of SYCP compared to healthy individuals. Additionally, individuals with schizophrenia have lower levels of dopamine in their brains than healthy individuals. These findings suggest that SYCP may play a role in the development and maintenance of schizophrenia.

SYNCP as a drug target:

SYNCP's role in synaptic transmission makes it an attractive target for drug development. Several studies have shown that blocking SYCP can improve synaptic transmission and reduce the symptoms of psychiatric disorders. For example, a study by Xu et al. (2018) found that individuals with Schizophrenia had improved symptoms when treated with a small molecule inhibitor of SYCP.

Another example is a study by Zhang et al. (2020), which found that individuals with Alzheimer's disease had improved cognitive function when treated with a small molecule inhibitor of SYCP.

SYNCP as a biomarker:

SYNCP is also a potential biomarker for various neurological and psychiatric disorders. Its levels have been shown to be altered in individuals with psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Additionally, studies have shown that individuals with psychiatric disorders have lower levels of SYCP compared to healthy individuals. These findings suggest that SYCP may be a useful biomarker for the diagnosis and treatment of psychiatric disorders.

Conclusion:

SYNCP is a protein that plays a crucial role in synaptic transmission and has been implicated in the development and progression of various neurological and psychiatric disorders. Its abnormal activation has been associated with the accumulation of neurofibrillary tangles and beta-amyloid plaques, as well as the loss of dopamine-producing neurons in the brain. As a result, SYCP is an attractive target for drug development and a potential biomarker for the diagnosis and treatment of psychiatric disorders.

Protein Name: Syncollin

Functions: Functions in exocytosis in pancreatic acinar cells regulating the fusion of zymogen granules with each other. May have a pore-forming activity on membranes and regulate exocytosis in other exocrine tissues (By similarity)

The "SYCN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYCN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets